Gautami Aggarwal

So my question is that to reach the USD375 in the U.S. by FY28 from currently USD284 million as FY26 base, you effectively need to add around USD90 million to USD115 million in 8 quarters. So can you just walk us through the bridge how you -- as to how to come from controlled substance -- how much will come from controlled substance , dormant ANDA relaunches, OTC launches, etcetera?